FRUTIGA
Regimen
- Experimental
- fruquintinib (oral VEGFR TKI) + paclitaxel
- Control
- placebo + paclitaxel
Population
Chinese patients with advanced G/GEJ adenocarcinoma progressing after first-line platinum and fluoropyrimidine
Key finding
mPFS 5.6 vs 2.7 mo (HR 0.57, p<0.0001, MET); mOS 9.6 vs 8.4 mo (HR 0.96, p=0.6064, NOT MET); ORR 42.4% vs 22.4%
Source: PMID 38734867
Timeline
Guideline citations
- CSCO GASTRIC 2025 (p.102)⚠️ OCR source